Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, Walsh AM, Baxi V, Pandya D, Baradet T, Locke D, Wu Q, Reilly TP, Phillips P, Nagineni V, Gianino N, Gu J, Zhao H, Perez-Gracia JL, Sanmamed MF, Melero I. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nature Medicine 2020, 26: 688-692. PMID: 32405062, PMCID: PMC8127102, DOI: 10.1038/s41591-020-0856-x.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalBiomarkers, PharmacologicalBiomarkers, TumorCell Cycle CheckpointsCohort StudiesFemaleHumansInterleukin-8MaleNeoplasmsNeutrophil InfiltrationNeutrophilsPrognosisProtein Kinase InhibitorsRetrospective StudiesSurvival AnalysisTreatment FailureTumor MicroenvironmentUp-RegulationConceptsSerum IL-8 levelsImmune checkpoint inhibitorsIL-8 levelsAdvanced cancerSerum interleukin-8 levelsPhase 3 clinical trialsSerum interleukin-8Interleukin-8 levelsLarge-scale retrospective analysisNeutrophil infiltrationWorse prognosisClinical benefitPoor outcomeIndependent biomarkerTumor immunobiologyClinical trialsInterleukin-8Retrospective analysisPatientsCancerInhibitorsIpilimumabNivolumabEverolimusPrognosis